Ubiquitination/de-ubiquitination: A promising therapeutic target for PTEN reactivation in cancer
- PMID: 35314212
- DOI: 10.1016/j.bbcan.2022.188723
Ubiquitination/de-ubiquitination: A promising therapeutic target for PTEN reactivation in cancer
Abstract
Tumor suppressor activation or reactivation has long been a sought-after, yet elusive, therapeutic strategy for human cancer. Phosphatase and tensin homolog (PTEN) is one of the most frequently mutated tumor suppressor genes that regulate many biological processes, including proliferation, survival, cellular architecture, motility, energy metabolism, and genomic stability. As a dose-dependent tumor suppressor, subtle reductions in PTEN protein levels and activity will alter the gene-expression profiles involved in tumor progression, laying the foundation for PTEN reactivation in cancer treatment. However, treatment strategies that manipulate and/or replace PTEN activity to successfully block and reverse the destructive progression of cancer are not yet available. Ubiquitination/de-ubiquitination is one of the major regulatory mechanisms of PTEN by influencing its stability, subcellular localization, and activity. Recent discoveries, including new ubiquitination sites, E3 ubiquitin ligases, de-ubiquitinases of PTEN, and participation of accessory and adaptor proteins, have revealed new modes of PTEN ubiquitination regulation. Furthermore, either pharmaceutical or gene-targeted inhibition of E3 ligase-mediated ubiquitination of PTEN potently releases PTEN's anticancer activity and suppresses tumorigenesis. These findings shed light on therapeutic strategies for reactivating PTEN in cancer that target ubiquitination/de-ubiquitination. Therefore, a comprehensive understanding of the ubiquitination/de-ubiquitination regulation of PTEN could help improve clinical conceptualization and treatment of cancer. This review aimed to summarize and discuss recent discoveries on PTEN ubiquitination and de-ubiquitination, with the goal of providing a systematic summary in the field and promoting clinical transformation of targeting ubiquitination for PTEN reactivation in the treatment of cancer.
Keywords: PI3K/Akt signaling; PTEN; PTEN reactivation; Ubiquitination; de-ubiquitination.
Copyright © 2022. Published by Elsevier B.V.
Similar articles
-
The HECT family of E3 ubiquitin ligases and PTEN.Semin Cancer Biol. 2022 Oct;85:43-51. doi: 10.1016/j.semcancer.2021.06.012. Epub 2021 Jun 12. Semin Cancer Biol. 2022. PMID: 34129913 Free PMC article. Review.
-
Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway.Science. 2019 May 17;364(6441):eaau0159. doi: 10.1126/science.aau0159. Science. 2019. PMID: 31097636 Free PMC article.
-
The equilibrium of tumor suppression: DUBs as active regulators of PTEN.Exp Mol Med. 2022 Nov;54(11):1814-1821. doi: 10.1038/s12276-022-00887-w. Epub 2022 Nov 16. Exp Mol Med. 2022. PMID: 36385557 Free PMC article. Review.
-
WWP2 is a physiological ubiquitin ligase for phosphatase and tensin homolog (PTEN) in mice.J Biol Chem. 2018 Jun 8;293(23):8886-8899. doi: 10.1074/jbc.RA117.001060. Epub 2018 Apr 23. J Biol Chem. 2018. PMID: 29685889 Free PMC article.
-
PIASxα ligase enhances SUMO1 modification of PTEN protein as a SUMO E3 ligase.J Biol Chem. 2014 Feb 7;289(6):3217-30. doi: 10.1074/jbc.M113.508515. Epub 2013 Dec 16. J Biol Chem. 2014. PMID: 24344134 Free PMC article.
Cited by
-
Semisynthetic Approach to the Analysis of Tumor Suppressor PTEN Ubiquitination.J Am Chem Soc. 2023 Mar 22;145(11):6039-6044. doi: 10.1021/jacs.2c13871. Epub 2023 Mar 10. J Am Chem Soc. 2023. PMID: 36897111 Free PMC article.
-
Lysine N-methyltransferase SETD7 promotes bladder cancer progression and immune escape via STAT3/PD-L1 cascade.Int J Biol Sci. 2023 Jul 16;19(12):3744-3761. doi: 10.7150/ijbs.87182. eCollection 2023. Int J Biol Sci. 2023. PMID: 37564199 Free PMC article.
-
PTEN: a new dawn in Parkinson's disease treatment.Front Cell Neurosci. 2025 Mar 10;19:1497555. doi: 10.3389/fncel.2025.1497555. eCollection 2025. Front Cell Neurosci. 2025. PMID: 40129459 Free PMC article. Review.
-
Post-Translational Modification of PTEN Protein: Quantity and Activity.Oncol Rev. 2024 Jul 31;18:1430237. doi: 10.3389/or.2024.1430237. eCollection 2024. Oncol Rev. 2024. PMID: 39144161 Free PMC article. Review.
-
Diverse roles of UBE2S in cancer and therapy resistance: Biological functions and mechanisms.Heliyon. 2024 Jan 18;10(2):e24465. doi: 10.1016/j.heliyon.2024.e24465. eCollection 2024 Jan 30. Heliyon. 2024. PMID: 38312603 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials